These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 21082766

  • 1. Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
    Khanfar MA, Hill RA, Kaddoumi A, El Sayed KA.
    J Med Chem; 2010 Dec 23; 53(24):8534-45. PubMed ID: 21082766
    [Abstract] [Full Text] [Related]

  • 2. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability.
    Saitoh M, Kunitomo J, Kimura E, Iwashita H, Uno Y, Onishi T, Uchiyama N, Kawamoto T, Tanaka T, Mol CD, Dougan DR, Textor GP, Snell GP, Takizawa M, Itoh F, Kori M.
    J Med Chem; 2009 Oct 22; 52(20):6270-86. PubMed ID: 19775160
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors.
    Polgár T, Baki A, Szendrei GI, Keseru GM.
    J Med Chem; 2005 Dec 15; 48(25):7946-59. PubMed ID: 16335919
    [Abstract] [Full Text] [Related]

  • 7. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
    Fang J, Huang D, Zhao W, Ge H, Luo HB, Xu J.
    J Chem Inf Model; 2011 Jun 27; 51(6):1431-8. PubMed ID: 21615159
    [Abstract] [Full Text] [Related]

  • 8. Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors.
    Koryakova AG, Ivanenkov YA, Ryzhova EA, Bulanova EA, Karapetian RN, Mikitas OV, Katrukha EA, Kazey VI, Okun I, Kravchenko DV, Lavrovsky YV, Korzinov OM, Ivachtchenko AV.
    Bioorg Med Chem Lett; 2008 Jun 15; 18(12):3661-6. PubMed ID: 18502121
    [Abstract] [Full Text] [Related]

  • 9. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY.
    Bioorg Med Chem Lett; 2012 Dec 01; 22(23):7232-6. PubMed ID: 23099099
    [Abstract] [Full Text] [Related]

  • 10. Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
    Vadivelan S, Sinha BN, Tajne S, Jagarlapudi SA.
    Eur J Med Chem; 2009 Jun 01; 44(6):2361-71. PubMed ID: 18929433
    [Abstract] [Full Text] [Related]

  • 11. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
    Lo Monte F, Kramer T, Gu J, Brodrecht M, Pilakowski J, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B.
    Eur J Med Chem; 2013 Mar 01; 61():26-40. PubMed ID: 22749643
    [Abstract] [Full Text] [Related]

  • 12. Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents.
    Wang M, Liu T, Chen S, Wu M, Han J, Li Z.
    Eur J Med Chem; 2021 Jan 01; 209():112874. PubMed ID: 33017743
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
    Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B.
    J Med Chem; 2012 May 10; 55(9):4407-24. PubMed ID: 22533818
    [Abstract] [Full Text] [Related]

  • 16. 3D-QSAR and docking studies of selective GSK-3beta inhibitors. Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3beta ligands.
    Lescot E, Bureau R, Sopkova-de Oliveira Santos J, Rochais C, Lisowski V, Lancelot JC, Rault S.
    J Chem Inf Model; 2005 May 10; 45(3):708-15. PubMed ID: 15921460
    [Abstract] [Full Text] [Related]

  • 17. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching.
    Conde S, Pérez DI, Martínez A, Perez C, Moreno FJ.
    J Med Chem; 2003 Oct 23; 46(22):4631-3. PubMed ID: 14561081
    [Abstract] [Full Text] [Related]

  • 18. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
    Dessalew N, Patel DS, Bharatam PV.
    J Mol Graph Model; 2007 Mar 23; 25(6):885-95. PubMed ID: 17018257
    [Abstract] [Full Text] [Related]

  • 19. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
    Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, Zalloum H, Al-Masri IM, Atallah N.
    J Med Chem; 2008 Apr 10; 51(7):2062-77. PubMed ID: 18324764
    [Abstract] [Full Text] [Related]

  • 20. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors.
    Akhtar M, Bharatam PV.
    Chem Biol Drug Des; 2012 Apr 10; 79(4):560-71. PubMed ID: 22168279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.